Testing effectiveness (Phase 2)Ended earlyNCT01116232
What this trial is testing
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+5 more
Barbara Ann Karmanos Cancer Institute 4